# PureTech Health Affiliate Vedanta Biosciences Awarded $5.8 Million CARB-X Grant

- Link: https://www.directorstalkinterviews.com/puretech-health-affiliate-vedanta-biosciences-awarded-5-8-million-carb-x-grant/412799989
- Published: 2019-12-05T07:27:32+00:00
- Author: Giles Arbor

**PureTech Health plc** (LON: PRTC) a clinical stage biotechnology company dedicated
to discovering, developing and commercialising highly differentiated medicines for
devastating diseases, has today noted that its affiliate, Vedanta Biosciences, has
been awarded a $5.8 million grant for its VE707 programme targeting multi-drug resistant
infections. The grant was awarded by Combating Antibiotic-Resistant Bacteria Biopharmaceutical
Accelerator (CARB-X), a global non-profit partnership dedicated to accelerating 
early development in antibacterial R&D to address the rising global threat of drug-
resistant bacteria. Vedanta Biosciences is eligible for $3.5 million in further 
funding upon completion of specific milestones.

> **Bharatt Chowrira, JD, PhD, president and chief of business and strategy at PureTech
> Health said:**
> “Increasingly the human microbiome is being colonised by dangerous bacteria and
> other microorganisms that have developed resistance to antimicrobial drugs, mainly
> through poor global stewardship of antibiotics. This grant from CARB-X recognises
> Vedanta’s unique platform and advanced understanding of the human gut microbiome
> for developing live biotherapeutic products with the potential to modulate the
> intestinal microbiome to address a range of significant human diseases and health
> issues, including drug-resistant pathogens.”

Share on: